Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 3,506 Shares of Stock

Key Points

• Insider sale: EVP Mark Schneyer sold 3,506 shares on May 4 at an average price of $21.79 for proceeds of $76,395.74, reducing his stake by 5.03% to 66,145 shares (≈$1.44M), as disclosed in an SEC Form 4 filing.
• Recent results: ACADIA beat expectations with $1.60 EPS (vs. $0.12 est.) and $298M in revenue (+9.4% YoY), and the company has a market cap of about $3.83B and a P/E of 9.76.
• Market and analyst context: Shares traded at $22.35 (50-/200-day MAs $22.20/$23.88), institutional ownership is ~96.7% with several large recent stakes, and analysts show a consensus "Moderate Buy" with a $31.21 target.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark Schneyer sold 3,506 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the sale, the executive vice president directly owned 66,145 shares of the company's stock, valued at approximately $1,441,299.55. This trade represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock traded up $0.16 on Tuesday, hitting $22.35. 1,030,907 shares of the company traded hands, compared to its average volume of 1,677,688. ACADIA Pharmaceuticals Inc. has a 52 week low of $14.45 and a 52 week high of $28.35. The business has a 50-day simple moving average of $22.20 and a 200 day simple moving average of $23.88. The stock has a market capitalization of $3.83 billion, a P/E ratio of 9.76, a price-to-earnings-growth ratio of 22.90 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 12.49%. The firm had revenue of $298.00 million for the quarter, compared to the consensus estimate of $292.54 million. During the same quarter in the previous year, the firm earned $0.86 earnings per share. The company's quarterly revenue was up 9.4% compared to the same quarter last year. Research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.45 earnings per share for the current year.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ACAD. Braidwell LP purchased a new stake in ACADIA Pharmaceuticals during the 3rd quarter valued at $50,760,000. Norges Bank purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter valued at $40,266,000. Millennium Management LLC raised its holdings in ACADIA Pharmaceuticals by 2,052.1% during the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company's stock valued at $31,652,000 after buying an additional 1,414,315 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in ACADIA Pharmaceuticals by 390.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company's stock valued at $35,187,000 after buying an additional 1,312,426 shares during the period. Finally, Logos Global Management LP purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter valued at $22,704,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on ACAD. Oppenheimer reissued a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. Royal Bank Of Canada lowered their target price on shares of ACADIA Pharmaceuticals from $31.00 to $30.00 and set an "outperform" rating on the stock in a report on Thursday, February 26th. Weiss Ratings downgraded shares of ACADIA Pharmaceuticals from a "hold (c+)" rating to a "hold (c)" rating in a report on Friday. Wolfe Research began coverage on shares of ACADIA Pharmaceuticals in a report on Monday, February 23rd. They issued an "outperform" rating and a $33.00 target price on the stock. Finally, Mizuho raised shares of ACADIA Pharmaceuticals from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $29.00 to $35.00 in a report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.21.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.